5 proven ways to lose weight in NYC
FDA-Approved Weight-Loss Options: A Complete Guide to Pills, GLP-1 Injections and Medical Weight Loss
There is no single “best” weight-loss treatment for everyone. The right plan depends on your health, appetite, previous results, medication risks, sleep, insurance benefits, budget and preference for a pill or injection.
Obesity is a chronic, relapsing disease influenced by biology, environment, sleep, medications, hormones, genetics and behavior. It is not simply a lack of willpower. Even a sustained loss of about 5% to 10% of starting weight may improve blood pressure, blood sugar, triglycerides, mobility and other weight-related risks. Larger losses may offer additional benefits for selected patients.
Before choosing a medication, a clinician should review body-mass index (BMI), waist circumference, medical and surgical history, pregnancy plans, blood pressure, pulse, kidney and liver health, current medications, eating patterns and symptoms of sleep apnea. W8MD combines these findings with the patient’s preferences and financial considerations to build an individualized plan.
The six evidence-based components of obesity treatment
1. Personalized nutrition
A sustainable calorie deficit can be created through a balanced reduced-calorie diet, lower-carbohydrate or low-glycemic plan, Mediterranean-style eating, structured meal replacements, or a medically supervised low-calorie diet. Adequate protein, fiber, fluids and micronutrients matter—especially during rapid weight loss.
2. Physical activity
Aerobic activity supports health and energy expenditure, while resistance training helps preserve muscle. The safest starting point depends on mobility, cardiovascular status and previous activity. Exercise alone usually produces modest scale loss, but it is important for health and long-term maintenance.
3. Behavioral and environmental support
Self-monitoring, meal planning, stimulus control, sleep scheduling and problem-solving can help turn short-term changes into routines. Binge-eating symptoms, depression or other concerns may require dedicated behavioral-health care.
4. Prescription medication
FDA-approved anti-obesity medications include oral and injectable options with different benefits, risks and costs. They should be selected after a medical evaluation and monitored for effectiveness and adverse effects.
5. Sleep and metabolic care
Untreated sleep apnea may worsen fatigue, appetite regulation and cardiometabolic health. W8MD offers sleep consultations and home sleep studies and can coordinate care for prediabetes, PCOS, fatty liver risk and other weight-related conditions.
6. Metabolic or bariatric procedures
Endoscopic procedures or bariatric surgery may provide the greatest average weight loss for appropriately selected patients. They require careful evaluation, lifelong nutritional monitoring and a maintenance strategy.
FDA-approved medications for chronic weight management
The list below focuses on medications with a U.S. FDA indication for weight management as of the editorial date. Eligibility and labeling differ by age, BMI, diagnosis and product. Average trial results cannot predict an individual result, and comparisons across separate trials are imperfect.
| Medication | Type | Typical role | Important considerations |
|---|---|---|---|
| Wegovy (semaglutide) | Weekly GLP-1 injection; an oral Wegovy tablet is also available | Chronic weight management; certain cardiovascular-risk indications | Nausea, vomiting, constipation or diarrhea may occur. It carries a boxed warning concerning thyroid C-cell tumors and is contraindicated with certain histories. Dose escalation and long-term planning are important. |
| Zepbound (tirzepatide) | Weekly dual GIP/GLP-1 injection | Chronic weight management; also approved for moderate-to-severe obstructive sleep apnea in adults with obesity | Often produces greater average trial weight loss than older medications, but gastrointestinal effects, contraindications, access and cost must be considered. It also carries a thyroid C-cell tumor boxed warning. |
| Foundayo (orforglipron) | Once-daily non-peptide oral GLP-1 medicine | Chronic weight management for qualifying adults | A new oral option for people who prefer not to inject. Product-specific prescribing information, interactions, tolerability and coverage should be reviewed. |
| Saxenda (liraglutide) | Daily GLP-1 injection | Chronic weight management | An established option, but daily administration and generally lower average weight loss than newer weekly incretin therapies may affect preference. |
| Qsymia (phentermine/topiramate ER) | Once-daily oral combination | Appetite reduction and chronic weight management | One of the more effective oral options. Pregnancy prevention and testing are essential because topiramate can cause fetal harm. Heart rate, mood, cognition, sleep and eye symptoms require consideration. |
| Contrave (naltrexone/bupropion ER) | Oral combination | May help hunger and reward-driven cravings | Not appropriate with uncontrolled hypertension, seizure disorders, certain eating disorders, chronic opioid use or abrupt withdrawal from certain substances. It contains the antidepressant-class suicidality warning. |
| Xenical or Alli (orlistat) | Prescription or lower-dose OTC capsule | Reduces absorption of some dietary fat | Oily stools, urgency and other gastrointestinal effects are common; fat-soluble vitamin supplementation and drug-interaction review may be needed. |
| Imcivree (setmelanotide) | Injection | Selected rare genetic obesity disorders—not routine obesity | Requires confirmation of an eligible genetic diagnosis and specialist management. |
How much weight can different medications produce?
Approximate averages from pivotal trials, when medication was combined with diet and physical-activity counseling, provide a useful comparison. Trial designs and populations differed, so these numbers are not head-to-head promises.
| Option | Approximate average result seen in major trials | Practical perspective |
|---|---|---|
| Tirzepatide / Zepbound | Roughly 15% to 21% at 72 weeks in adults without diabetes, depending on dose | Among the strongest average medication results; weekly injection and dose-related cost/tolerability matter. |
| Semaglutide / Wegovy injection | About 15% at 68 weeks in a major adult trial without diabetes | Strong evidence base; also has a cardiovascular-risk-reduction indication for qualifying adults. |
| Oral GLP-1 therapies | Product- and dose-specific; newer oral therapies can produce clinically meaningful double-digit average loss in trials | May suit patients preferring a pill, but administration, tolerability, coverage and exact label differ. |
| Phentermine/topiramate ER | Approximately 8% to 10% after about one year at commonly studied doses | Among the strongest established oral combinations and may be much more affordable. |
| Liraglutide / Saxenda | Approximately 5% to 8% around one year | Daily injection with a longer clinical history, but generally less average loss than weekly semaglutide or tirzepatide. |
| Naltrexone/bupropion / Contrave | Approximately 5% to 6% around one year | May be useful for selected craving patterns when no contraindication exists. |
| Orlistat | Usually modest additional loss compared with lifestyle treatment alone | Non-stimulant and available OTC at a lower dose; gastrointestinal effects can limit use. |
Results vary substantially. Diabetes, adherence, maximum tolerated dose, treatment duration, nutrition, activity, sleep and medication discontinuation all affect outcomes. Losing weight faster is not always safer or better; preserving muscle and maintaining the result matter.
What about Ozempic, Mounjaro and off-label medications?
- Ozempic contains semaglutide but is FDA-approved for type 2 diabetes and certain related risk-reduction indications—not specifically as the weight-management brand. Wegovy is the semaglutide weight-management product.
- Mounjaro contains tirzepatide and is approved for type 2 diabetes. Zepbound is the tirzepatide weight-management product.
- Topiramate alone and metformin may be used off-label in selected situations, such as medication-associated weight gain, prediabetes or PCOS, but neither should be described as universally FDA-approved for obesity by itself.
- A clinician may prescribe an approved drug off-label when medically appropriate, but the patient should understand the intended use, evidence, alternatives and insurance implications.
Compounded and investigational products are different
Compounded semaglutide or tirzepatide products are not FDA-approved and are not generic versions of Wegovy or Zepbound. Compounding may be legally appropriate in limited patient-specific circumstances, but compounded products do not undergo FDA premarket review for safety, effectiveness or quality. Patients should ask exactly what product, concentration and pharmacy are involved.
Retatrutide, CagriSema, MariTide, aleniglipron and other pipeline medicines should be described as investigational unless and until the FDA approves a specific product. Promising study results do not establish approval, availability or safety outside a legitimate clinical trial.
How W8MD physicians choose among weight-loss options
W8MD does not start with a favorite brand. The clinical team considers the whole patient and may recommend medication, nutrition-only treatment, sleep care, or referral for a procedure. The evaluation may include:
- BMI, waist pattern, previous weight trajectory and personal goals
- Prediabetes, type 2 diabetes, PCOS, fatty liver risk, hypertension and cholesterol
- Cardiovascular disease, kidney or gallbladder history, pancreatitis history and gastrointestinal symptoms
- Current medications, drug interactions, mood, seizures, glaucoma and thyroid history
- Pregnancy, breastfeeding or plans to become pregnant
- Hunger, cravings, binge-eating symptoms and food preferences
- Snoring, daytime sleepiness and possible obstructive sleep apnea
- Preference for tablets versus injections, insurance formulary, prior authorization and total cost
The most effective medication is one that is medically appropriate, affordable enough to continue, tolerable, and paired with a realistic long-term maintenance plan.
Affordable physician-supervised options
Semaglutide-based pathway
$29.99/week and upwith insurance accepted for qualifying visitsSelf-pay starts at $59.99/week and up.
Tirzepatide-based pathway
$45/week and upwith insurance accepted for qualifying visitsSelf-pay starts at $69.99/week and up.
Generic phentermine/topiramate
$59.99 biweeklywith insurance accepted for a qualifying visitSelf-pay starts at $75 biweekly.
Insurance support
Prior authorizationfor eligible patients whose plan covers medicationApproval is never guaranteed and plan rules vary.
Medical evaluation required. Eligibility, product, dose, pharmacy, supply, labs, shipping, insurance benefits and total price vary. “Starting from” pricing generally applies to starting-dose pathways and may increase with dose. Ask for the complete cost before treatment.
Insurance coverage: what patients should know
Many plans cover obesity screening or clinician visits, but that does not mean every plan covers every anti-obesity medication. Employer exclusions, formularies, deductibles and prior-authorization rules differ. W8MD accepts many insurance plans for qualifying visits and can submit prior-authorization documentation when a patient is eligible and the benefit exists.
Before enrolling, ask four separate questions: Is the medical visit covered? Is the prescribed drug on the formulary? What clinical criteria must be met? What will the medication, visit, laboratory work and supplies cost at the current dose and at higher doses?
Sleep, nutrition and maintaining weight loss
Medication can reduce appetite, but it cannot replace adequate nutrition or restorative sleep. W8MD integrates medical weight loss with sleep-medicine services, home sleep studies when appropriate, protein and hydration planning, IV/IM nutrition services when clinically indicated, activity counseling and maintenance care.
Weight regain is common after stopping an effective medication because the biological drivers of obesity can return. Before starting treatment, discuss duration, affordability, the lowest effective long-term strategy, muscle preservation and what will happen if insurance coverage changes.
“Fantastic program. Truly a life changer!”
D.M., W8MD patient success story
D.M. reported losing 100 pounds and maintaining the loss for more than ten years. Individual results vary, and one patient’s experience does not predict another patient’s outcome.
W8MD locations
Frequently asked questions
Who may qualify for prescription weight-loss medication?
Many chronic weight-management medicines are labeled for adults with obesity (often BMI 30 or greater) or overweight (often BMI 27 or greater) plus at least one weight-related condition. Each product has its own label, contraindications and age criteria. BMI is a screening measure, not the entire evaluation.
Which FDA-approved medication causes the most weight loss?
In separate major trials, tirzepatide and semaglutide produced substantially greater average weight loss than most older medicines. This does not make them safest or best for every person. Medical history, side effects, access, cost and the ability to maintain treatment matter.
Is phentermine/topiramate still a useful option?
Yes. It remains one of the most effective established oral approaches and can be considerably less expensive than many branded incretin medicines. It is inappropriate during pregnancy and requires careful review of cardiovascular, eye, mood, cognitive and other risks.
Can I take a GLP-1 medicine with another weight-loss drug?
Do not combine medications on your own. Some combinations are specifically discouraged or have not been adequately studied. A qualified prescriber must assess interactions, overlapping adverse effects and whether a combination has a reasonable clinical rationale.
Are Ozempic and Mounjaro approved for weight loss?
They are diabetes brands. Wegovy is the semaglutide weight-management brand, and Zepbound is the tirzepatide weight-management brand. Clinicians sometimes prescribe drugs off-label, but the distinction should be explained accurately.
Are compounded semaglutide and tirzepatide FDA-approved?
No. Compounded products are not FDA-approved and are not FDA-approved generic versions of Wegovy or Zepbound. Ask the prescriber to identify the exact product, concentration, source and reason for compounding.
Will insurance pay for my medication?
Coverage varies widely. A plan may cover the visit but exclude anti-obesity drugs, or it may require a documented BMI, related condition and previous treatment. W8MD can help eligible patients with prior authorization when the benefit exists, but approval cannot be guaranteed.
How long do I need treatment?
Obesity is generally chronic. Some patients need long-term pharmacotherapy, while others transition to a different medicine or structured maintenance plan. Stopping treatment can lead to renewed hunger and weight regain, so duration should be discussed before starting.
Can W8MD help if I also snore or feel sleepy during the day?
Yes. W8MD provides integrated sleep evaluation and may arrange a home sleep study when appropriate. Identifying sleep apnea can improve safety and address a common weight-related condition.
Comments
Post a Comment